AngelMD

OraQ AI is a clinical decision support system established in 2021 and headquartered in Alberta, Canada. The company focuses on empowering patients by enhancing treatment strategies and providing advanced assessments and detailed risk profiling. Utilizing the capabilities of artificial intelligence and machine learning, OraQ AI's platform aims to transform the way dental professionals engage with, diagnose, and treat patients holistically. This innovative approach enables healthcare providers to verify, validate, and improve their treatment recommendations, ultimately promoting better wellness practices among patients.

Raydiant Oximetry, Inc. is a medical device company founded in 2015 and headquartered in Mountain View, California. The company focuses on improving childbirth outcomes for mothers and infants by developing a low-cost, non-invasive device that monitors fetal oxygen levels during labor. This innovative technology aims to provide real-time insights into fetal oxygenation, which can help clinicians make informed decisions and reduce the risks associated with childbirth, such as birth injuries and unnecessary cesarean sections. By enhancing patient care and potentially lowering healthcare costs, Raydiant Oximetry's device addresses critical needs in maternal and fetal health.

Neumentum, Inc. is a pharmaceutical company based in Palo Alto, California, focused on the development and commercialization of non-opioid analgesic and neurology products. Founded in 2017, Neumentum aims to provide safe and effective alternatives to traditional opioid pain management, addressing significant unmet needs in both acute and chronic pain treatment. The company holds global rights to five novel non-opioid pain products, with its most advanced candidates being two phase 3-ready injectable formulations intended for acute postsurgical pain. Through its innovative platform, Neumentum is dedicated to offering viable options for patients, thereby mitigating the risks of misuse and addiction associated with opioid medications.

Access Vascular, Inc., founded in 2015 and based in Bedford, Massachusetts, specializes in the development of venous access devices that utilize innovative hydrogel materials to prevent thrombosis, infections, and other complications associated with intravenous therapy. The company’s portfolio includes a range of products such as peripherally inserted central catheters, hemodialysis devices, implantable ports, and drug delivery systems. Access Vascular's technology aims to enhance clinical outcomes while reducing healthcare costs by minimizing the risk of blood clots and associated complications. Their flagship product, the HydroPICC, is designed to outperform existing technologies, potentially leading to shorter hospital stays and improved patient experiences. By addressing common challenges in venous access, Access Vascular seeks to improve the effectiveness and safety of intravenous treatments.

Raydiant Oximetry, Inc. is a medical device company founded in 2015 and headquartered in Mountain View, California. The company focuses on improving childbirth outcomes for mothers and infants by developing a low-cost, non-invasive device that monitors fetal oxygen levels during labor. This innovative technology aims to provide real-time insights into fetal oxygenation, which can help clinicians make informed decisions and reduce the risks associated with childbirth, such as birth injuries and unnecessary cesarean sections. By enhancing patient care and potentially lowering healthcare costs, Raydiant Oximetry's device addresses critical needs in maternal and fetal health.

Iterion Therapeutics, Inc. is a clinical-stage biotechnology company based in Houston, Texas, focused on developing targeted therapeutics for cancer treatment. Founded in 2010, the company specializes in innovative cancer therapies, with its leading product, Tegavivint, being a selective inhibitor of the Wnt/b-catenin signaling pathway. This pathway is known to play a significant role in processes such as cell proliferation and immune evasion. Tegavivint has shown pre-clinical efficacy in various cancer models, including desmoid tumors, acute myeloid leukemia, osteosarcoma, and several solid tumors. Iterion is currently conducting a Phase I clinical study for Tegavivint in patients with desmoid tumors across multiple clinical sites in the United States and Canada, aiming to provide effective treatment options for patients with challenging cancers.

LifeSprout is developing the next generation of synthetic soft tissue substitutes for aesthetic and reconstructive medicine. They offer revolutionary products for aesthetic and regenerative medicine. They have created a platform that looks and behaves like the body’s own tissues. The company is turning this into a suite of products for millions of patients each year with soft tissue losses from aging, cancer, and metabolic disease.

Sensulin, LLC is an Oklahoma-based company that focuses on developing glucose-responsive insulin for the treatment of type I and type II diabetes. Utilizing its proprietary Agglomerated Vesicle Technology, the company creates a drug delivery platform that employs liposomes linked by a stimulus-responsive molecule. This innovative approach aims to mimic the functionality of a healthy human pancreas, potentially allowing for a true once-a-day insulin solution. Sensulin's insulin formulation seeks to eliminate the necessity for separate basal and prandial insulin, significantly reducing the need for glucose monitoring and multiple daily injections, thereby improving the quality of life for individuals living with diabetes. Established in 2011, Sensulin is dedicated to advancing diabetes care through its groundbreaking research and development efforts.

Fibralign Corporation specializes in the development of advanced biomedical devices using its proprietary Nanoweave® scaffolding technology. This innovative approach allows Fibralign to create products that mimic human tissue structure, influencing cell behavior and collagen fiber orientation to support the body's regenerative processes. The company's first product, the BioBridge® Collagen Matrix, is currently undergoing clinical studies to assess its effectiveness in treating and preventing secondary lymphedema. Additionally, Fibralign is focused on research and development for new applications, including treatments for ischemia and novel delivery systems for stem cells and gene therapy.

Access Vascular, Inc., founded in 2015 and based in Bedford, Massachusetts, specializes in the development of venous access devices that utilize innovative hydrogel materials to prevent thrombosis, infections, and other complications associated with intravenous therapy. The company’s portfolio includes a range of products such as peripherally inserted central catheters, hemodialysis devices, implantable ports, and drug delivery systems. Access Vascular's technology aims to enhance clinical outcomes while reducing healthcare costs by minimizing the risk of blood clots and associated complications. Their flagship product, the HydroPICC, is designed to outperform existing technologies, potentially leading to shorter hospital stays and improved patient experiences. By addressing common challenges in venous access, Access Vascular seeks to improve the effectiveness and safety of intravenous treatments.

Otomagnetics, Inc., based in Rockville, Maryland, develops a magnetic injection delivery system aimed at providing non-invasive drug delivery to challenging areas of the body, including the inner and middle ear, the eye, and the skin. Founded in 2012 as a spin-out from the University of Maryland College Park, the company addresses the difficulty of delivering therapies to the inner ear, which is shielded by the blood-labyrinth barrier. In preclinical studies, Otomagnetics' proprietary technology has successfully demonstrated the ability to deliver therapeutic agents to the inner ear, enhancing dosing and efficacy in models of tinnitus and noise-induced hearing loss. Additionally, the system has shown promise for treating middle ear conditions, such as otitis media, without the need for invasive procedures. While Otomagnetics' products are still experimental and not yet approved for human use, they represent a significant advancement in the field of targeted drug delivery.

Qool Therapeutics, Inc. specializes in the development of non-invasive temperature management therapies aimed at inducing therapeutic hypothermia. Founded in 2005 and headquartered in Menlo Park, California, the company focuses on creating efficient solutions that preserve cells, improve patient quality of life, and extend life. Its innovative device operates by preserving tissue and modulating various cell functions, which helps to slow inflammation, limit cell damage, and reduce oxygen requirements for cells. This technology provides medical professionals with a safe and straightforward option for managing patient care.

Noninvasix, Inc. is a medical technology company based in Galveston, Texas, that specializes in non-invasive precision oximetry for measuring brain oxygenation in preterm infants within neonatal intensive care units. Founded in 2007 by Dr. Donald Prough and Dr. Rinat Esenaliev at the University of Texas Medical Branch, the company has developed a novel optoacoustic platform technology that allows for continuous monitoring of oxygen sufficiency in organs and veins without the need for invasive procedures. This technology is particularly useful in diagnosing and managing conditions such as sepsis and septic shock, enabling clinicians to assess tissue hypoxia in real-time and adjust treatments accordingly. Noninvasix has received over $6.8 million in funding, including substantial grants from the NIH and DOD, and has been recognized in various prestigious accelerator programs. The company's innovations have been validated in multiple peer-reviewed studies, and its intellectual property includes numerous patents both in the U.S. and internationally.

KPI Therapeutics, Inc. is a biotechnology company specializing in the development of therapies for unmet medical needs, particularly in the fields of autoimmunity and chronic pain. The company offers several drug candidates, including dalazatide, KPI-150, and KPI-190, targeting systemic autoimmune diseases such as lupus, as well as a CSP conopeptide aimed at managing chronic pain. Founded in 2013 and based in Seattle, Washington, KPI Therapeutics collaborates with various partners, including Kineta, Inc., Chimera Biotec, and the University of Washington School of Medicine, to enhance drug development and improve access to new treatments. The company is committed to accelerating the progression of promising drug candidates through critical stages of development, addressing significant gaps in patient care.

Kineta, Inc. is a clinical stage biotechnology company based in Seattle, Washington, focused on the development of immunology-based therapeutics for oncology, neuroscience, and virology. The company is advancing a range of innovative therapies, including KCP-506, a non-opioid antagonist for chronic pain, and LHF-535, an oral antiviral targeting Lassa and other arenaviruses by inhibiting viral entry and replication. Kineta is also engaged in developing next-generation immunotherapies, exemplified by KVA12.1, a VISTA blocking immunotherapy designed to reprogram the immune system to combat cancer. With strategic partnerships with notable organizations like Pfizer and Genentech, Kineta aims to leverage its expertise in antiviral therapies and immune modulation to address significant medical challenges. Formerly known as Lecura, Inc., the company was founded in 2007.